Search Result

Results for "

progesterone receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Progesterone Receptor (78) 17β-HSD (1) Akt (1) Aldose Reductase (1) Androgen Receptor (14) Apoptosis (4) Autophagy (14) CDK (1) Drug Derivative (1) Drug Isomer (1) Drug Metabolite (2) EGFR (1) Endogenous Metabolite (9) Estrogen Receptor/ERR (9) FKBP (3) Fluorescent Dye (1) GABA Receptor (2) Glucocorticoid Receptor (21) Glycosyltransferase (1) GnRH Receptor (1) HIV (4) IFNAR (2) Isotope-Labeled Compounds (19) Mineralocorticoid Receptor (8) Neurokinin Receptor (3) NF-κB (1) NO Synthase (5) Oxytocin Receptor (1) p38 MAPK (1) PARP (1) Phosphatase (1) PROTACs (2) Reference Standards (13) Sigma Receptor (1)
By Research Areas:	Cancer (50) Cardiovascular Disease (10) Endocrinology (58) Infection (3) Inflammation/Immunology (11) Metabolic Disease (15) Neurological Disease (16)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (1)

108

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Progesterone Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13683

Mifepristone Maximum Cited Publications 71 Publications Verification RU486; RU 38486	Endogenous Metabolite Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy	Endocrinology Cancer
Mifepristone (RU486) is a **progesterone receptor** (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-B0469

Medroxyprogesterone acetate 30+ Cited Publications Medroxyprogesterone 17-acetate; Farlutin	Progesterone Receptor Androgen Receptor Glucocorticoid Receptor Endogenous Metabolite	Endocrinology Cancer
Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with *progesterone, androgen* and glucocorticoid receptors .

HY-111372

Finerenone 5+ Cited Publications BAY 94-8862	Mineralocorticoid Receptor	Cardiovascular Disease Metabolic Disease
Finerenone (BAY 94-8862) is a third-generation, selective, and orally active nonsteroidal *mineralocorticoid receptor* (MR) antagonist (IC₅₀** = 18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (> 500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-158101

BMS-986365 1 Publications Verification CC-94676	PROTACs Androgen Receptor	Cancer
BMS-986365 (CC-94676) is an orally active and selective targeted androgen receptor (AR) PROTAC degrader (DC₅₀ of 10-40 nM). BMS-986365 is capable of inducing cereblon (CRBN) E3 ligase-dependent ubiquitination and degradation of the androgen receptor (AR), as well as various AR mutants. BMS-986365 shows no degradation of the close AR family members estrogen receptor (ER), progesterone receptor (PR), and glucocorticoid receptor (GR). BMS-986365 shows significant in vivo potency, degrading AR, inhibiting AR signaling, and restricting tumor growth in animal models of advanced prostate cancer. BMS-986365 can be used for the study of metastatic castration-resistant prostate cancer (mCRPC) .

HY-B0084

Dienogest 2 Publications Verification STS 557	Progesterone Receptor	Endocrinology
Dienogest (STS-557) is an orally active and selective progesterone receptor agonist that effectively reduces the gene expression of COX-2, mPGES-1 and aromatase. Dienogest also inhibits the mRNA and protein expression of PGE₂ synthase and the activation of NF-κB. Dienogest can be used in studies of endometriosis, menopause and menorrhagia .

HY-13676

Megestrol acetate 2 Publications Verification	Progesterone Receptor Autophagy HIV	Endocrinology Cancer
Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .

HY-109171

Elinzanetant NT-814; BAY3427080	Neurokinin Receptor	Cardiovascular Disease Neurological Disease
Elinzanetant is an orally active and selective NK-1 and NK-3 receptor antagonist. Elinzanetant alleviates menopause-associated vasomotor symptoms, including hot flashes and night sweats. Elinzanetant reduces estradiol and progesterone levels. Elinzanetant can be used for the research of moderate to severe vasomotor and sleep disorders associated with menopause .

HY-16508

Ulipristal acetate 4 Publications Verification CDB-2914	Progesterone Receptor Autophagy	Metabolic Disease Cancer
Ulipristal acetate (CDB-2914) is an orally active, selective **progesterone receptor** modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma .

HY-B0111

Drospirenone 1 Publications Verification Dihydrospirorenone	Progesterone Receptor Androgen Receptor	Endocrinology Cancer
Drospirenone (Dihydrospirorenone) is an orally active fourth-generation progestin that interacts with the **progesterone receptor** (PR) and androgen receptor (AR). Drospirenone significantly decreases both plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) via the AR. Drospirenone can produce DNA damage in bone marrow cells of female mice. .

HY-119384

Promegestone 1 Publications Verification R-5020; Surgestone	Progesterone Receptor	Endocrinology Cancer
Promegestone (R-5020), a progestin, is a potent progesterone receptor (PR) agonist. Promegestone has the potential for endocrine regulation and cancer research .

HY-111372R

Finerenone (Standard) BAY 94-8862 (Standard)	Reference Standards Mineralocorticoid Receptor	Cardiovascular Disease
Finerenone (Standard) is the analytical standard of Finerenone. This product is intended for research and analytical applications. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal *mineralocorticoid receptor* (MR) antagonist (IC₅₀*=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor* (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-B0648

Medroxyprogesterone 5+ Cited Publications 17α-Hydroxy-6α-methylprogesterone; U8840	Progesterone Receptor	Endocrinology Cancer
Medroxyprogesterone (17α-Hydroxy-6α-methylprogesterone) is a synthetic human variant of progesterone that is a progesterone receptor agonist with oral activity. Medroxyprogesterone can induce cell proliferation through the PI3K/Akt signaling pathway. Medroxyprogesterone has an inhibitory effect on atherosclerosis in mice. The progesterone agonist activity of Medroxyprogesterone is less effective than Medroxyprogesterone acetate (HY-B0469) .

HY-B1095

Chlormadinone acetate 1 Publications Verification	Progesterone Receptor Androgen Receptor Glucocorticoid Receptor GABA Receptor	Neurological Disease Metabolic Disease
Chlormadinone acetate is a progestogen with potent progestogenic activity and antiandrogenic effects. Chlormadinone acetate acts on glucocorticoid receptor, progesterone receptor, androgen receptor, and GABA_A receptor. Chlormadinone acetate induces endometrial proliferation in estrogen-pretreated rabbits, inhibits testosterone-stimulated growth of the prostate and seminal vesicles in castrated rats, and reduces the thymus and adrenal weights in juvenile rats. Chlormadinone acetate is applicable to research related to diseases such as depression and reproductive metabolic disorders .

HY-105634A

Nomegestrol acetate	Progesterone Receptor	Endocrinology Cancer
Nomegestrol acetate is an orally active, highly selective progestogen and a **progesterone receptor** complete agonist. Nomegestrol acetate inhibits ovulation. Nomegestrol acetate is also effective in inhibiting the proliferation of human endometrial cancer RL95-2 cells in vitro and in vivo. Nomegestrol acetate can be used in cancer (especially endometrial cancer) and contraceptive studies .

HY-B0742

Hydroxyprogesterone caproate 5+ Cited Publications 17α-Hydroxyprogesterone hexanoate; 17α-Hydroxyprogesterone caproate	Progesterone Receptor	Endocrinology
Hydroxyprogesterone caproate (17α-Hydroxyprogesterone hexanoate; 17α-Hydroxyprogesterone caproate) is a progesterone receptor (progesterone *receptor) ligand and steroid hormone transcription inhibitor. Hydroxyprogesterone caproate downregulates estrogen receptors* in target tissues and activates their metabolic pathways, and exhibits equivalent affinity for progesterone receptor A and progesterone receptor B. Hydroxyprogesterone caproate shows no consistent teratogenicity or developmental toxicity in rat, mouse and monkey models, but induces resorption or abortion in rhesus monkeys at human-equivalent doses. Hydroxyprogesterone caproate promotes the production of TNF-α in lipopolysaccharide-stimulated whole blood from non-pregnant women. Hydroxyprogesterone caproate can be used in scientific research related to preterm birth .

HY-14959

Ulipristal CDB-3236; Deacetyl CDB-2914	Progesterone Receptor	Endocrinology Cancer
Ulipristal (CDB 3236) is a selective **progesterone receptor** modulator (SPRM). Ulipristal binds to the progesteron receptor, thereby inhibiting PR-mediated gene expression, and interfering with progesterone activity in the reproductive system .

HY-W011890

Cridanimod 1 Publications Verification	Progesterone Receptor IFNAR	Inflammation/Immunology Cancer
Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression. Cridanimod is a small-molecule immunomodulator and interferon inducer .

HY-13071

Nestoron 1 Publications Verification ST-1435; Elcometrine	Progesterone Receptor	Endocrinology
Nestoron (ST-1435) is a 19-norprogesterone derivative with high affinity and selectivity for **progesterone receptors**. Nestoron is a highly selective and potent progestogen that can be used as a hormonal contraceptive .

HY-B1834

Megestrol	Progesterone Receptor Glucocorticoid Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
Megestrol is an orally active glucocorticoid and progesterone receptor agonist. Megestrol can alleviate anorexia, cachexia or unexplained significant weight loss associated with acquired immunodeficiency syndrome (AIDS). Megestrol may cause manifestations similar to those of glucocorticoids and increase the risk of mental disorders .

HY-14234

Glucocorticoid receptor agonist 1 Publications Verification	Glucocorticoid Receptor	Metabolic Disease Inflammation/Immunology Endocrinology
Glucocorticoid receptor agonist is a Glucocorticoid receptor agonist that acts on Glucocorticoid receptor (GR), progesterone receptor (PR) and mineralocorticoid receptor (MR) with the IC₅₀ values of 2.1 , 1200 and 210 nM, respectively. Glucocorticoid receptor agonist has steroid-like anti-inflammatory properties and may be used to improve metabolism and reduce increased levels of body fat and serum insulin .

HY-B0652

Etonogestrel 3-Oxodesogestrel; 3-keto-Desogestrel	Drug Metabolite Estrogen Receptor/ERR Progesterone Receptor Endogenous Metabolite FKBP	Endocrinology
Etonogestrel (3-Oxodesogestrel), a biologically active metabolite of progestin Desogestrel, binds with high affinity to **progesterone receptors** and estrogen receptors in the target organs . Etonogestrel induce FKBP51 mRNA and protein expression in cultured human endometrial stromal cells (HESCs) .

HY-W587861

5β-Dihydroprogesterone 1 Publications Verification 5βDHP	Oxytocin Receptor	Endocrinology
5β-Dihydroprogesterone (5βDHP) is the metabolite of Progesterone (HY-N0437). 5β-Dihydroprogesterone binds to oxytocin receptor, reduces the Oxytocin (HY-17571)-induced calcium signal transduction, thereby exhibiting the tocolytic activity .

HY-15606

Tanaproget 1 Publications Verification NSP-989	Progesterone Receptor	Endocrinology
Tanaproget is an orally effective, selective nonsteroidal progesterone receptor (PR) agonist targeting human PR with an IC₅₀ of 1.7 nM. Tanaproget promotes the interaction between PR receptors and coactivators (such as SRC-1), thereby inhibiting the secretion of matrix metalloproteinases (MMP-3/MMP-7) and reducing endometrial tissue invasion and angiogenesis. Tanaproget can be used for contraception and endometriosis inhibition research .

HY-13676R

Megestrol acetate (Standard) 2 Publications Verification	Reference Standards Progesterone Receptor Autophagy HIV	Endocrinology Cancer
Megestrol acetate (Standard) is the analytical standard of Megestrol acetate. This product is intended for research and analytical applications. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .

HY-139659

ARD-61	PROTACs Androgen Receptor Progesterone Receptor Apoptosis	Cancer
ARD-61 is a highly potent, effective and specific *PROTAC androgen receptor* (AR)** degrader. ARD-61 potently and effectively induces AR and progesterone receptors (PR) degradation in AR+ cancer cell lines. ARD-61 induces apoptosis and effectively induces tumor growth inhibition in the MDA-MB-453 xenograft model in mice . ARD-61 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-119433

Asoprisnil J867	Progesterone Receptor	Endocrinology
Asoprisnil (J867), a selective **progesterone receptor** modulator, exhibits mixed progesterone agonist and antagonist effects on various progesterone targeted tissues in animal and human .

HY-11028

PF-02413873 PF-2413873	Progesterone Receptor	Endocrinology
PF-02413873 (PF-2413873) is a potent selective, fully competitive and orally active nonsteroidal progesterone receptor (PR) antagonist, with a K_i of 2.6 nM. PF-02413873 can block progesterone binding and PR nuclear translocation, and inhibit endometrial growth in vivo .

HY-13683R

Mifepristone (Standard) Maximum Cited Publications 71 Publications Verification RU486 (Standard); RU 38486 (Standard)	Reference Standards Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy	Endocrinology Cancer
Mifepristone (Standard) is the analytical standard of Mifepristone. This product is intended for research and analytical applications. Mifepristone (RU486) is a **progesterone receptor** (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-123352

ZK 216348 (+)-ZK 216348	Glucocorticoid Receptor	Inflammation/Immunology Endocrinology
ZK 216348 ((+)-ZK 216348) is a nonsteroidal selective glucocorticoid receptor agonist with an IC₅₀ of 20.3 nM. ZK 216348 also binds to Progesterone and mineralocorticoid receptors with IC₅₀s of 20.4 nM and 79.9 nM, respectively. ZK 216348 has antiinflammatory activity similar to Prednisolone and induces less transactivation-mediated side effects .

HY-106389

Onapristone ZK 98299	Progesterone Receptor	Cancer
Onapristone is a **progesterone receptor antagonist, with K_d*s of 11.6 nM and 11.90 nM for human endometrium and myometrium progesterone* receptor in saturation analysis. Onapristone has antitumor activity .

HY-16775

Vilaprisan BAY 1002670	Progesterone Receptor	Cancer
Vilaprisan is a selective progesterone receptor modulator (SPRM), which targets **progesterone receptors. Vilaprisan can inhibit cell proliferation and stimulate apoptosis**. Vilaprisan has oral efficacy and anti-proliferative activity against uterine leiomyoma (UF ).

HY-B0469R

Medroxyprogesterone acetate (Standard) 30+ Cited Publications Medroxyprogesterone 17-acetate(Standard); Farlutin (Standard)	Reference Standards Progesterone Receptor Androgen Receptor Glucocorticoid Receptor Endogenous Metabolite	Endocrinology Cancer
Medroxyprogesterone acetate (Standard) is the analytical standard of Medroxyprogesterone acetate. This product is intended for research and analytical applications. Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with *progesterone, androgen* and glucocorticoid receptors .

HY-121012

(rac)-AG-205	NF-κB Akt	Endocrinology
(rac)-AG-205 is a potent inhibitor of progesterone receptor membrane component 1 (Pgrmc1) that induces genes involved in sterol synthesis, including the INSIG1 protein, which forms a complex with PGRMC1. (rac)-AG-205 prevents neuronal resistance to hypoxic ischaemia by blocking NF-kB signalling and activation of the BDNF/PI3K/AKT pathway .

HY-157493

PR antagonist 1	Progesterone Receptor	Endocrinology
PR antagonist 1 (compound 8) is a selective progesterone receptor (PR) antagonist, and can be used for the research of a variety of progesterone-related diseases and disorders such as endometriosis and uterine fibroids .

HY-B0742R

Hydroxyprogesterone caproate (Standard) 5+ Cited Publications 17α-Hydroxyprogesterone hexanoate(Standard); 17α-Hydroxyprogesterone caproate (Standard)	Reference Standards Progesterone Receptor	Others
Hydroxyprogesterone caproate (Standard) is the analytical standard of Hydroxyprogesterone caproate. This product is intended for research and analytical applications. Hydroxyprogesterone caproate (17α-Hydroxyprogesterone hexanoate; 17α-Hydroxyprogesterone caproate) is a progesterone receptor (progesterone *receptor) ligand and steroid hormone transcription inhibitor. Hydroxyprogesterone caproate downregulates estrogen receptors* in target tissues and activates their metabolic pathways, and exhibits equivalent affinity for progesterone receptor A and progesterone receptor B. Hydroxyprogesterone caproate shows no consistent teratogenicity or developmental toxicity in rat, mouse and monkey models, but induces resorption or abortion in rhesus monkeys at human-equivalent doses. Hydroxyprogesterone caproate promotes the production of TNF-α in lipopolysaccharide-stimulated whole blood from non-pregnant women. Hydroxyprogesterone caproate can be used in scientific research related to preterm birth .

HY-B0469S

Medroxyprogesterone acetate-d3 1 Publications Verification Medroxyprogesterone 17-acetate-d₃; Farlutin-d₃	Progesterone Receptor Androgen Receptor Glucocorticoid Receptor	Endocrinology Cancer
Medroxyprogesterone acetate-d₃ is deuterium labeled Medroxyprogesterone acetate. Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with progesterone, androgen and glucocorticoid receptors .

HY-13683S

Mifepristone-d3 RU486-d₃; RU 38486-d₃	Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy	Endocrinology Cancer
Mifepristone-d₃ is the deuterium labeled Mifepristone. Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-17649

EIDD-036	Progesterone Receptor	Neurological Disease
EIDD-036, is the blood-brain barrier penetrant C-20 oxime of Progesterone (HY-N0437), that binds progesterone receptor (PR) with an IC₅₀ of 171 nM. EIDD-036 is the active metabolite of EIDD-1723 (HY-125547). EIDD-036 exhibits promising challenges for rapid administration in acute trauma. EIDD-036 can be used for the study of traumatic brain injury (TBI) .

HY-111302

Norgestrienone	Progesterone Receptor	Endocrinology
Norgestrienone is a progestin receptor agonist. Norgestrienone is commonly used as a progesterone compound in birth control pills and can be combined with ethinylestradiol. Norgestrienone is a click chemical. It contains Alkyne groups and can undergo copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc) with molecules containing Azide groups. Norgestrienone can be used in the study of hereditary angioneurotic edema .

HY-12073

WAY-255348	Progesterone Receptor	Endocrinology Cancer
W-255348 is an effective non-steroidal progesterone receptor (PR) antagonist that acquires antagonist activity by binding to and subsequently blocking progesterone induced nuclear accumulation, phosphorylation, and PR promoter interactions. WAY-255348 can be used in the research of reproductive disorders or PR-positive breast cancer .

HY-N7424

4,7-Dihydroxycoumarin 4,7-DHC	EGFR Estrogen Receptor/ERR Progesterone Receptor	Cancer
4,7-Dihydroxycoumarin is an EGFR inhibitor, estrogen receptor inhibitor, and **progesterone receptor inhibitor. 4,7-Dihydroxycoumarin against breast cancer cells with an IC₅₀** velue of 18.36 μg/mL. 4,7-Dihydroxycoumarin can be used for the research of breast cancer .

HY-125547

EIDD-1723	Progesterone Receptor	Neurological Disease Endocrinology
EIDD-1723 is a Progesterone (HY-N0437) analogues, that binds progesterone receptor (PR) with an IC₅₀ of 2.25 μM. EIDD-1723 is the prodrug of EIDD-036 (HY-17649). EIDD-1723 may exert its neuroprotective effects not solely through progesterone receptor (PR)-dependent pathways but also via non-genomic mechanisms, such as modulation of inflammatory responses and oxidative stress. EIDD-1723 can be used for the study of traumatic brain injury (TBI) .

HY-13683S2

Mifepristone-d6 RU486-d₆; RU 38486-d₆	Glucocorticoid Receptor Autophagy Endogenous Metabolite NO Synthase Progesterone Receptor Isotope-Labeled Compounds	Endocrinology Cancer
Mifepristone-d₆ is deuterated labeled Mifepristone (HY-13683). Mifepristone (RU486) is a **progesterone receptor** (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-B0084S2

Dienogest-d6 STS 557-d₆	Isotope-Labeled Compounds Progesterone Receptor Autophagy Apoptosis	Endocrinology Cancer
Dienogest-d₆ is deuterium labeled Dienogest (HY-B0084). Dienogest is an orally active progesterone receptor agonist that can be used in the study of endometriosis ^.

HY-111372A

(Rac)-Finerenone (Rac)-BAY 94-8862	Mineralocorticoid Receptor	Cardiovascular Disease
(Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold) .

HY-12738

PF-3882845	Mineralocorticoid Receptor Progesterone Receptor	Cardiovascular Disease Metabolic Disease
PF-3882845 is a remarkably high affinity selective and orally efficacious mineralocorticoid receptor (MR binding IC₅₀=2.7 nM) antagonist for hypertension and nephropathy. PF-3882845 also binds to **progesterone receptor (PR) with the binding IC₅₀** of 310 nM .

HY-14250

PF-998425	Androgen Receptor	Endocrinology
PF-998425 is a potent, selective nonsteroidal *androgen receptor* (AR) antagonist with an IC₅₀** of 37 nM and 43 nM in AR binding and cellular assays, respectively. PF-998425 has low activity on common receptors and enzymes, such as progesterone receptor. PF-998425 can be used for sebum control and androgenetic alopecia research .

HY-111372S

Finerenone-d3 BAY 94-8862-d₃	Mineralocorticoid Receptor	Others
Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal *mineralocorticoid receptor* (MR) antagonist (IC₅₀*=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor* (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-111372S1

Finerenone-d5 1 Publications Verification BAY 94-8862-d₅	Isotope-Labeled Compounds Mineralocorticoid Receptor	Cardiovascular Disease
Finerenone-d₅ (BAY 94-8862-d₅) is deuterium labeled Finerenone. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal *mineralocorticoid receptor* (MR) antagonist (IC₅₀*=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor* (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-131547

Org OD 02-0 10-Ethenyl-19-norprogesterone	Progesterone Receptor p38 MAPK	Endocrinology
Org OD 02-0 (10-Ethenyl-19-norprogesterone) is a membrane progesterone receptor α (mPRα)-specific agonist (IC₅₀: 33.9 nM). Org OD 02-0 activates MAPK activity. Org OD 02-0 inhibits prolactin (PRL) secretion in the pituitary .

Cat. No.	Product Name

HY-L074

Anti-Breast Cancer Compound Library

3,181 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 3,181 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0469

Medroxyprogesterone acetate 30+ Cited Publications Medroxyprogesterone 17-acetate; Farlutin	Classification of Application Fields Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	Progesterone Receptor Androgen Receptor Glucocorticoid Receptor Endogenous Metabolite
Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with *progesterone, androgen* and glucocorticoid receptors .

HY-B0652

Etonogestrel 3-Oxodesogestrel; 3-keto-Desogestrel	Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Steroids Source Classification	Drug Metabolite Estrogen Receptor/ERR Progesterone Receptor Endogenous Metabolite FKBP
Etonogestrel (3-Oxodesogestrel), a biologically active metabolite of progestin Desogestrel, binds with high affinity to **progesterone receptors** and estrogen receptors in the target organs . Etonogestrel induce FKBP51 mRNA and protein expression in cultured human endometrial stromal cells (HESCs) .

HY-B0469R

Medroxyprogesterone acetate (Standard) 30+ Cited Publications Medroxyprogesterone 17-acetate(Standard); Farlutin (Standard)	Classification of Application Fields Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	Reference Standards Progesterone Receptor Androgen Receptor Glucocorticoid Receptor Endogenous Metabolite
Medroxyprogesterone acetate (Standard) is the analytical standard of Medroxyprogesterone acetate. This product is intended for research and analytical applications. Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with *progesterone, androgen* and glucocorticoid receptors .

HY-B0652R

Etonogestrel (Standard) 3-Oxodesogestrel (Standard); 3-keto-Desogestrel (Standard)	Structural Classification Endogenous metabolite Steroids Source Classification	Drug Metabolite Reference Standards Estrogen Receptor/ERR Progesterone Receptor Endogenous Metabolite FKBP
Etonogestrel (Standard) is the analytical standard of Etonogestrel. This product is intended for research and analytical applications. Etonogestrel (3-Oxodesogestrel), a biologically active metabolite of progestin Desogestrel, binds with high affinity to progesterone receptors and estrogen receptors in the target organs . Etonogestrel induce FKBP51 mRNA and protein expression in cultured human endometrial stromal cells (HESCs) .

HY-131586

3,7-Dihydroxyflavone Resogalangin	Flavonoids Flavones Plants Fabaceae Zuccagnia punctata Cav. Source Classification	17β-HSD Estrogen Receptor/ERR Aldose Reductase
3,7-Dihydroxyflavone (Resogalangin) is a flavonoid phytoestrogen, which can be isolated from Adenophora species. 3,7-Dihydroxyflavone is a modulator of estrogen receptors and an inhibitor of human progesterone metabolizing enzyme AKR1C1 and fungal 17β-hydroxysteroid dehydrogenase and a redox inhibitor (IC₅₀=0.6 and 6.0 μM, respectively). 3,7-Dihydroxyflavone is a fluorescent binding substrate for human serum albumin (HSA) with excitation wavelengths of 370 nm (pH 7.4) and 350 nm (pH 3.5), respectively, and emission wavelength of 515 nm .

Cat. No.	Product Name	Chemical Structure

HY-B0469S

Medroxyprogesterone acetate-d3 1 Publications Verification
Medroxyprogesterone acetate-d₃ is deuterium labeled Medroxyprogesterone acetate. Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with progesterone, androgen and glucocorticoid receptors .

HY-13683S

Mifepristone-d3
Mifepristone-d₃ is the deuterium labeled Mifepristone. Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-13683S2

Mifepristone-d6
Mifepristone-d₆ is deuterated labeled Mifepristone (HY-13683). Mifepristone (RU486) is a **progesterone receptor** (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-B0084S2

Dienogest-d6
Dienogest-d₆ is deuterium labeled Dienogest (HY-B0084). Dienogest is an orally active progesterone receptor agonist that can be used in the study of endometriosis ^.

HY-111372S

Finerenone-d3

Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-111372S1

Finerenone-d5

1 Publications Verification

Finerenone-d₅ (BAY 94-8862-d₅) is deuterium labeled Finerenone. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-B0648S

Medroxyprogesterone-d3
Medroxyprogesterone-d₃ is the deuterium labeled Medroxyprogesterone. Medroxyprogesterone is a progestin, a synthetic variant of the human hormone progesterone and a potent progesterone receptor agonist.

HY-B0652S1

Etonogestrel-d6
Etonogestrel-d₆ is deuterium labeled Etonogestrel. Etonogestrel (3-Oxodesogestrel), a biologically active metabolite of progestin Desogestrel, binds with high affinity to progesterone receptors and estrogen receptors in the target organs . Etonogestrel induce FKBP51 mRNA and protein expression in cultured human endometrial stromal cells (HESCs) .

HY-16508S

Ulipristal acetate-d6
Ulipristal acetate-d₆ is deuterium labeled Ulipristal acetate. Ulipristal acetate (CDB-2914) is an orally active, selective progesterone receptor modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma .

HY-B0251S

Eplerenone-d3
Eplerenone-d₃ is the deuterium labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, competitive and oreally active aldosterone antagonist with an IC₅₀ of 138 nM. Eplerenone has low affinity for progesterone, androgen, estrogen and glucocorticoid receptors. Eplerenone can be used for hypertension and heart failure after myocardial infarction reserch .

HY-13676S

Megestrol acetate-d3

Megestrol acetate-d₃ is the deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .

HY-14959S

Ulipristal-d3
Ulipristal-d₃ (CDB-3236-d₃) is deuterium labeled Ulipristal. Ulipristal (CDB 3236) is a selective **progesterone receptor** modulator (SPRM). Ulipristal binds to the progesteron receptor, thereby inhibiting PR-mediated gene expression, and interfering with progesterone activity in the reproductive system .

HY-B1095S1

Chlormadinone acetate-d6-1

Chlormadinone acetate-d₆-1 is deuterium labeled Chlormadinone acetate (HY-B1095). Chlormadinone acetate is a progestogen with potent progestogenic activity and antiandrogenic effects. Chlormadinone acetate acts on glucocorticoid receptor, progesterone receptor, androgen receptor, and GABA_A receptor. Chlormadinone acetate induces endometrial proliferation in estrogen-pretreated rabbits, inhibits testosterone-stimulated growth of the prostate and seminal vesicles in castrated rats, and reduces the thymus and adrenal weights in juvenile rats. Chlormadinone acetate is applicable to research related to diseases such as depression and reproductive metabolic disorders .

HY-B1095S2

Chlormadinone acetate-d3

Chlormadinone acetate-d₃ is the deuterium labeled Chlormadinone acetate (HY-B1095). Chlormadinone acetate is a progestogen with potent progestogenic activity and antiandrogenic effects. Chlormadinone acetate acts on glucocorticoid receptor, progesterone receptor, androgen receptor, and GABA_A receptor. Chlormadinone acetate induces endometrial proliferation in estrogen-pretreated rabbits, inhibits testosterone-stimulated growth of the prostate and seminal vesicles in castrated rats, and reduces the thymus and adrenal weights in juvenile rats. Chlormadinone acetate is applicable to research related to diseases such as depression and reproductive metabolic disorders .

HY-B1834S1

Megestrol-d5
Megestrol-d₅ is the deuterium labeled Megestrol. Megestrol is an orally active glucocorticoid and progesterone receptor agonist. Megestrol can alleviate anorexia, cachexia or unexplained significant weight loss associated with acquired immunodeficiency syndrome (AIDS). Megestrol may cause glucocorticoid-like effects and an increased risk of mental disorders.

HY-13683S1

Mifepristone-13C,d3

Mifepristone- ¹³C,d₃ is the ¹³C- and deuterium labeled Mifepristone. Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay . Mifepristone-13C,d3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13676S1

Megestrol acetate-d3-1

Megestrol acetate-d₃-1 is deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .

HY-16508S1

Ulipristal acetate-d3
Ulipristal acetate-d₃ (CDB-2914-d₃) is deuterium labeled Ulipristal acetate. Ulipristal acetate (CDB-2914) is an orally active, selective **progesterone receptor** modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma .

HY-109171S

Elinzanetant-d3
Elinzanetant-d₃ (NT-814-d₃) is deuterium labeled Elinzanetant. Elizanetant (NT-814) is an orally active, selective NK-1,3 receptor antagonist. Elizanetant can reduce the levels of estradiol and progesterone, and is used in the study of vascular motor symptoms and sleep disorders related to menopause in women .

HY-106827S1

Trimegestone-13C,d3

Trimegestone- ¹³C,d₃ is ¹³C and deuterated labeled Trimegestone (HY-106827). Trimegestone (RU 27987) is an orally active 19-norpregnane progestin. Trimegestone binds to progesterone receptor (PR) with an IC₅₀ value of 3.3 nM (rat PR). Trimegestone increases alkaline phosphatase activity (EC₅₀=0.1 nM) but not luciferase activity. Trimegestone also shows a weak antiandrogenic activity (weak androgen receptor affinity). Trimegestone can be used in studies of contraception or menopausal syndromes .

HY-B0084S4

Dienogest-13C,15N,d4

Dienogest-13C,15N,d4 (STS 557-13C,15N,d4) is the ¹³C, ¹⁵N and deuterium labeled isotope of Dienogest (HY-B0084). Dienogest (STS-557) is an orally active and selective progesterone receptor agonist that effectively reduces the gene expression of COX-2, mPGES-1 and aromatase. Dienogest also inhibits the mRNA and protein expression of PGE₂ synthase and the activation of NF-κB. Dienogest can be used in studies of endometriosis, menopause and menorrhagia .

HY-B0742S1

Hydroxyprogesterone caproate-d8

Hydroxyprogesterone caproate-d₈ (17α-Hydroxyprogesterone hexanoate-d₈) is the deuterium labeled Hydroxyprogesterone caproate (HY-B0742). Hydroxyprogesterone caproate (17α-Hydroxyprogesterone hexanoate; 17α-Hydroxyprogesterone caproate) is a progesterone receptor (progesterone receptor) ligand and steroid hormone transcription inhibitor. Hydroxyprogesterone caproate downregulates estrogen receptors in target tissues and activates their metabolic pathways, and exhibits equivalent affinity for progesterone receptor A and progesterone receptor B. Hydroxyprogesterone caproate shows no consistent teratogenicity or developmental toxicity in rat, mouse and monkey models, but induces resorption or abortion in rhesus monkeys at human-equivalent doses. Hydroxyprogesterone caproate promotes the production of TNF-α in lipopolysaccharide-stimulated whole blood from non-pregnant women. Hydroxyprogesterone caproate can be used in scientific research related to preterm birth .

HY-B0469S1

Medroxyprogesterone acetate-d7
Medroxyprogesterone acetate-d₇ (Medroxyprogesterone 17-acetate-d₇) is the deuterium labeled Medroxyprogesterone acetate (HY-B0469) . Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with progesterone, androgen and glucocorticoid receptors .

Cat. No.	Product Name		Classification